Fidelity Investments
PRME icon

Fidelity Investments’s Prime Medicine PRME Stock Holding History

Fidelity Investments’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.5M Sell
1,761,884
-7,592
-0.4% -$25.2K ﹤0.01% 2320
2026
Q1 		$6.16M Sell
1,769,476
-407,170
-19% -$1.55M ﹤0.01% 2233
2025
Q4 		$7.55M Sell
2,176,646
-636,429
-23% -$2.83M ﹤0.01% 2138
2025
Q3 		$15.6M Sell
2,813,075
-931,352
-25% -$3.78M ﹤0.01% 1831
2025
Q2 		$9.25M Sell
3,744,427
-2,808
-0.1% -$4.33K ﹤0.01% 1962
2025
Q1 		$7.46M Sell
3,747,235
-54,793
-1% -$140K ﹤0.01% 2016
2024
Q4 		$11.1M Buy
3,802,028
+58,716
+2% +$206K ﹤0.01% 1905
2024
Q3 		$14.5M Sell
3,743,312
-184,541
-5% -$855K ﹤0.01% 1813
2024
Q2 		$20.2M Buy
3,927,853
+3,483
+0.1% +$21.1K ﹤0.01% 1649
2024
Q1 		$27.5M Sell
3,924,370
-976
-0% -$7.4K ﹤0.01% 1548
2023
Q4 		$34.8M Buy
3,925,346
+2,930
+0.1% +$22.6K ﹤0.01% 1430
2023
Q3 		$37.4M Sell
3,922,416
-116,803
-3% -$1.52M ﹤0.01% 1352
2023
Q2 		$59.2M Sell
4,039,219
-4,477,910
-53% -$62.5M 0.01% 1212
2023
Q1 		$105M Buy
8,517,129
+54,083
+0.6% +$881K 0.01% 967
2022
Q4 		$157M Buy
+8,463,046
New +$153M 0.02% 785

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Fidelity Investments's PRME Position: Q2 2026 in Review

Fidelity Investments reduced its Prime Medicine (PRME) stake by 0.43% in Q2 2026, selling an estimated $25.2K and leaving 1,761,884 shares worth $6.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2320.

Fidelity Investments first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $157M in Q4 2022. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Fidelity Investments held 1,761,884 shares of Prime Medicine worth $6.5M as of Q2 2026.
  • Fidelity Investments sold 7,592 Prime Medicine shares in Q2 2026, an estimated $25.2K.
  • Prime Medicine made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2320 holding.
  • Fidelity Investments first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • Fidelity Investments's Prime Medicine position peaked at $157M in Q4 2022.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.